DEVELOPMENT AND VALIDATION OF STABILITY INDICATING HPTLC METHOD FOR DETERMINATION OF PALIPERIDONE PALMITATE AS BULK DRUG

1Dr. Mrinalini C. Damle
Professor
Department of Quality Assurance
AISSMS College of Pharmacy, Savitribai Phule University, Kennedy Road, Near RTO, Pune 411001, Maharashtra, India

2Swapnil S. Waghmare
Research Scholar
Department of Quality Assurance
AISSMS College of Pharmacy, Savitribai Phule University, Kennedy Road, Near RTO, Pune 411001, Maharashtra, India

3Parushotam Sinha
Research and Development Department,
Wockhardt pharmaceuticals Pvt. Ltd., Aurangabad, Maharashtra, India.

Abstract:
A simple, economical and precise thin-layer chromatography method has been developed for determination of Paliperidone palmitate. The method was validated as per International Conference on Harmonization (ICH) guidelines. Aluminium TLC plates precoated with silica gel 60F254 were used as the stationary phase and chloroform: methanol 3:7 (v/v) as mobile phase. A compact band (Rf 0.54 ± 0.03) was obtained for Paliperidone palmitate. Densitometric analysis was performed in the absorbance mode at 236 nm. The calibration curve was found to be linear in the concentration range of 500–2500 ng/band. The limits of detection and quantitation were found to be 47.70 ng/band and 144.56 ng/band respectively. Paliperidone palmitate was subjected to stress conditions like hydrolysis under acidic, basic and neutral conditions, oxidation, heat and photolysis.

Keywords: Paliperidone Palmitate, HPTLC, Stability indicating method

INTRODUCTION
Paliperidone is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that Paliperidone and Risperidone act via similar if not the same pathways. It has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of central dopamine type 2 (D2) and serotonin type 2 (5HT2A) receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone chemically described as 3-[2-[4-(6-fluoro-1,2benzisoxazol-3yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-9-hydroxy-2-ethyl-4H-pyrido[1,2-alpyrimidin-4-one(Fig. I)][1].

1Dr. Mrinalini C. Damle
Professor
Department of Quality Assurance
AISSMS College of Pharmacy, Savitribai Phule University, Kennedy Road, Near RTO, Pune 411001, Maharashtra, India

2Swapnil S. Waghmare
Research Scholar
Department of Quality Assurance
AISSMS College of Pharmacy, Savitribai Phule University, Kennedy Road, Near RTO, Pune 411001, Maharashtra, India

3Parushotam Sinha
Research and Development Department,
Wockhardt pharmaceuticals Pvt. Ltd., Aurangabad, Maharashtra, India.
Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006 [2]. According to literature survey, there are few UV [3,4], stability indicating HPLC [5-8], HPLC [9-11], MS-MS [12], UPLC [13], RP-RRLC [14], LC-MS [15], ULC [16] methods were reported as bulk or in pharmaceutical formulation.

To the best of our knowledge, no stability indicating HPTLC method has been reported for the determination of Paliperidone palmitate as bulk drug. The objective of this research work was to develop a simple, economical and stability-indicating HPTLC method for the determination of Paliperidone palmitate as bulk drug.

MATERIALS AND METHODS

Chemicals and reagents
Paliperidone palmitate was provided as a gift sample by Wockhardt research and development centre, Aurangabad. Methanol, Chloroform and all other chemicals used in this study were of AR grade purchased from LOBA chemie Pvt. Ltd. Mumbai, India.

Instruments
Linnomat-5 sample applicator (Camag, Switzerland), twin trough chamber (10 x 10 cm; Camag, Switzerland), TLC scanner 3 (Camag, Switzerland), WinCATS version 1.4.3 software (Camag, Switzerland), Photostability chamber (Newtronics NEC103RSPI), Shimadzu balance (Model AY-120), Camag 100 µl sample syringe (Hamilton, Switzerland) were used in the study.

Preparation of standard solutions
Standard stock solution of Paliperidone palmitate was prepared by dissolving 10 mg of the drug in 10 ml of methanol to get concentration of 1000 µg/ml. From the standard stock solution, working standard solution was prepared containing 100 µg/ml of Paliperidone palmitate.

Selection of analytical wavelength
The standard solution of Paliperidone palmitate of concentration 100 µg/ml was prepared using methanol and scanned over the wavelength range 200 nm to 400 nm by using UV-Visible spectrophotometer. \( \lambda_{\text{max}} \) was found to be 236 nm (Fig. II).
Chromatographic conditions

Initially, mobile phase optimization trials were conducted using Toluene: ethyl acetate, chloroform: methanol in the various ratios. Optimized mobile phase was chloroform: methanol (3:7 v/v). TLC plates precoated with silica gel 60 F_{254}, of dimension 10 cm × 10 cm with 250 µm layer thickness were used as stationary phase. TLC plates were pre-washed with methanol and dried. The standard solution of Paliperidone palmitate was spotted on the dried, pre-coated TLC plate as a band with 4 mm width. The chromatographic development was carried out by using chloroform: methanol (3:7 v/v), as mobile phase with 15 min chamber saturation time and run up to distance 90 mm. Densitometric scanning was performed at 236 nm.

RESULTS AND DISCUSSION

Optimization of mobile phase

Method development for Paliperidone palmitate was started with the development of densitogram using neat solvents and combinations of toluene, ethyl acetate and methanol in different ratios. Chloroform: methanol in the ratio of (3: 7 v/v) was selected as mobile phase for Paliperidone palmitate which gives accepted peak parameters. The Rf was found to be 0.54 ± 0.03 for Paliperidone palmitate. The standard densitogram of Paliperidone palmitate (2500 ng/band) is shown in (Fig. III).

![Figure III. densitogram of standard solution of pal. palmitate (2500 ng/band)](image)

Stress degradation studies of bulk drug

Stress testing studies were carried out as per ICH Q1A (R2) [17] on how the quality of drug varies under various stress conditions like oxidation, hydrolysis, photolysis and thermal, etc. Optimization of stress conditions was done by changing the strength of reagent and duration of exposure to get 10-30 % degradation.

Optimization trials

Initially trials were conducted using various normalities of HCl and NaOH by keeping the sample solution overnight. For the thermal study sample was heated at 80°C for 4 h to 8 h and for oxidation, trials were conducted using 30 % H_2O_2 by keeping the sample solution overnight. It was observed that the drug gets degraded partially.

Optimized stress conditions

Alkaline hydrolysis

1 ml working standard solution of Paliperidone palmitate (1000 µg/ml) was mixed with 1 ml of 1 N NaOH and volume was made up to 10 ml with methanol. The solution was kept for overnight at room temperature. Average 75.45 % of Paliperidone palmitate was recovered with no peak of degradation.

Acid hydrolysis

1 ml standard solution of Paliperidone palmitate (1000 µg/ml) was mixed with 1 ml of 0.5 N HCl and volume was made up to 10 ml using methanol. The solution was kept for overnight at room temperature. Average 78.09 % of Paliperidone palmitate was recovered with no peak of degradation.
Oxidative degradation

1 ml standard solution of Paliperidone palmitate (1000 µg/ml) was mixed with 3 ml 30% v/v H$_2$O$_2$, volume was made up to 10 ml using methanol. The solution was kept for overnight at room temperature. Average 70.56 % of Paliperidone palmitate was recovered with no peak of degradation.

Degradation under dry heat

Dry heat study was performed by keeping the drug in hot air oven at 80 ºC for 8 hours. Average 81.80 % of Paliperidone palmitate was recovered with no peak of degradation.

Degradation under neutral condition

To 1 ml of 1000 µg/ml solution of Paliperidone palmitate, 1 ml of distilled water was added. The volume was made up to 10 ml with methanol. The solution was kept for overnight at room temperature. Average 89.15% of Paliperidone palmitate was recovered with no peak of degradation.

Photo-degradation studies

Photolytic degradation studies were carried out by exposure of drug to UV light up to 200 watt h/m$^2$ and subsequently to cool white fluorescent light to achieve an illumination of 1.2 million Lux hours. The sample was weighed, dissolved and diluted get 20 µg/ml as final concentration and was applied to TLC plate. After the photo degradation study under UV light 105.68% and Fluorescence light 108.81% Paliperidone palmitate was recovered with no peak of degradation. Spotting of 10000 ng/band was done for samples at each stress condition to locate peak for a degradation product if any.

<table>
<thead>
<tr>
<th>Stress degradation condition</th>
<th>% Recovery</th>
<th>% Degradation</th>
<th>Peak purity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid (0.5 N HCl) kept for overnight at RT</td>
<td>78.09</td>
<td>21.91</td>
<td>0.999</td>
</tr>
<tr>
<td>Base (1 N NaOH, overnight at RT)</td>
<td>75.45</td>
<td>24.55</td>
<td>0.999</td>
</tr>
<tr>
<td>Oxidation (30% v/v H$_2$O$_2$) overnight at RT</td>
<td>70.56</td>
<td>29.44</td>
<td>0.999</td>
</tr>
<tr>
<td>Neutral (kept for overnight at RT)</td>
<td>89.15</td>
<td>10.85</td>
<td>0.999</td>
</tr>
<tr>
<td>Dry heat (80 ºC 8 hr)</td>
<td>81.80</td>
<td>18.2</td>
<td>0.999</td>
</tr>
<tr>
<td>Photo stability UV 200 watt hrs/m2</td>
<td>105.68</td>
<td>-</td>
<td>0.999</td>
</tr>
<tr>
<td>Fluorescence 1.2 million lux. Hrs</td>
<td>108.81</td>
<td>-</td>
<td>0.997</td>
</tr>
</tbody>
</table>

Table I. summary of stress degradation study of paliperidone palmitate

VALIDATION PARAMETER

The developed method was successfully validated according to the ICH Q2 (R1) [18] guidelines.

Specificity

The specificity of the method was ascertained by analyzing standard drug and sample. The spot for the drug in a sample was confirmed by comparing the Rf and the spectra of the spot with that of the standard drug spot. The specificity of the method was also ascertained by peak purity profiling studies by analyzing the spectrum at peak start, middle and at the peak end.

Linearity and range

The calibration curve was obtained in the range of 500-2500 ng/band by applying different volumes (5-25 µl) of stock solution of (100 µg/ml) on a TLC plate. Each standard in five replicates was analyzed and peak areas were recorded. The relationship between peak area and concentration was established by the simple regression equation method. (Fig. IV). A)
Assay

20 tablets were accurately weighed and powdered. From the powder, an amount equivalent to 10 mg of Paliperidone palmitate was accurately weighed and transferred to 10 ml volumetric flask. Methanol was added, sonicated for 15 min, a solution was filtered. Dilutions were made to get the final concentration 100 µg/ml. The assay was calculated by extrapolation from standard curve which was found to be 98.67%.

Accuracy

To check accuracy of the method, recovery studies were carried out by adding a standard drug to sample at three different levels 80, 100, and 120%. Basic concentration of the sample chosen was 1000 ng/band. The drug concentrations were calculated by using the regression equation of Paliperidone Palmitate (Table-II).

<table>
<thead>
<tr>
<th>Concentration (ng/band)</th>
<th>Amount (ng/band)</th>
<th>% Recovery</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample conc</td>
<td>Amount added</td>
<td>Recovered</td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td>800</td>
<td>1769.70</td>
<td>98.31</td>
</tr>
<tr>
<td>1000</td>
<td>1000</td>
<td>1982.01</td>
<td>99.10</td>
</tr>
<tr>
<td>1000</td>
<td>1200</td>
<td>2207.62</td>
<td>100.34</td>
</tr>
</tbody>
</table>

Precision

The precision of the method was demonstrated by intra-day and inter-day studies. In the intra-day studies, 3 replicates of 3 standard solutions were analyzed in a same day and percentage RSD was calculated. For the inter-day, 3 standard solutions were analyzed on three consecutive days and percentage RSD was calculated (Table III & IV).

<table>
<thead>
<tr>
<th>Concentration (ng/band)</th>
<th>Area</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>500</td>
<td>1703.33</td>
<td>1.12</td>
</tr>
<tr>
<td>1000</td>
<td>3372.67</td>
<td>1.96</td>
</tr>
</tbody>
</table>
**Limit of detection (LOD) and limit of quantification (LOQ)**

LOD and LOQ were calculated as 3.3 $\sigma$/S and 10 $\sigma$/S respectively. Where $\sigma$ is the standard deviation of the lowest concentration response and S is the slope of the calibration plot. The LOD and LOQ were found to be 47.70 ng/band and 144.56 ng/band respectively.

**Robustness**

The robustness of the method were studied during method development, by small but deliberate variations in chamber saturation time (13, 17 min), change in mobile phase composition, Time was changed from spotting to development and development to scanning and the effect on the peak area was noted (Table V).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Robust Condition</th>
<th>Area</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chamber saturation time (15 min) ± 2 min</td>
<td>13 min</td>
<td>3586.5</td>
<td>0.72</td>
</tr>
<tr>
<td>Mobile phase composition chloroform: methanol (3:7 v/v) ± 0.2 methanol</td>
<td>Chloroform: methanol(3.2: 6.8 )</td>
<td>3039.27</td>
<td>1.51</td>
</tr>
<tr>
<td>Time from application to development (immediate)</td>
<td>After 30 min</td>
<td>3108.2</td>
<td>1.66</td>
</tr>
<tr>
<td>Time from development to scanning (immediate)</td>
<td>After 1 h</td>
<td>3214.07</td>
<td>1.59</td>
</tr>
</tbody>
</table>

n = number of determinations, %RSD = %Relative Standard Deviation

The method validation results were satisfactory as per ICH Q2 R1 guidelines. The peak area was found to be linear over the concentration range of 500-2500 ng/band with a correlation coefficient of 0.984. Method specificity can be proved using peak purity parameter in WinCATS software of HPTLC. There is a provision to compare the UV spectrum at the start, middle and end of any peak. Inter and Intra-day precision was less than 2%. Percent recovery in an accuracy study was within the limit of 98 to 102 %. The results of validation are summarized in table 6.

<table>
<thead>
<tr>
<th>Validation parameter</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearity</td>
<td>$Y = 3.25x + 178.3$</td>
</tr>
<tr>
<td></td>
<td>$R^2 = 0.984$</td>
</tr>
<tr>
<td>Range</td>
<td>500-2500 ng/band</td>
</tr>
<tr>
<td>Precision</td>
<td>(%) RSD</td>
</tr>
<tr>
<td>A) Intra-day</td>
<td>1.41</td>
</tr>
<tr>
<td>B) Inter-day</td>
<td>1.43</td>
</tr>
</tbody>
</table>

n = number of determinations, %RSD = %Relative Standard Deviation
Assay

<table>
<thead>
<tr>
<th>Accuracy</th>
<th>98.67%</th>
</tr>
</thead>
<tbody>
<tr>
<td>80%</td>
<td>100.42</td>
</tr>
<tr>
<td>100%</td>
<td>100.73</td>
</tr>
<tr>
<td>120%</td>
<td>99.51</td>
</tr>
<tr>
<td>LOD</td>
<td>47.70 ng/band</td>
</tr>
<tr>
<td>LOQ</td>
<td>144.56 ng/band</td>
</tr>
<tr>
<td>Specificity</td>
<td>Specific</td>
</tr>
<tr>
<td>Robustness</td>
<td>Robust</td>
</tr>
</tbody>
</table>

DISCUSSION

A thorough study of literature revealed few stability indicating methods by chromatographic techniques. The drug has been reported to be sensitive to hydrolytic conditions. A variation in observations was seen with respect to oxidative degradation conditions. Study by Divya I. et al indicates that the drug is stable to oxidation where as studies by Trivedi R. et al, Boga H. et al and Sherje A. et al reflect oxidative degradation to different extent. Studies by Trivedi R. et al and Sherje A. et al indicates the drug is stable to thermal and photolytic conditions. We have observed that Paliperidone is photo-stable but prone to other condition of degradation.

CONCLUSION

The developed method is simple and stability indicating. It can be used for estimation of Paliperidone palmitate. The method has inherent advantage of high throughput.

ACKNOWLEDGEMENT

Authors are thankful to the principal and management of the AISSMS College of pharmacy, Pune for providing required facilities for research work. Authors are also thankful to the Wockhardt pharmaceuticals Pvt. Ltd. Aurangabad for providing an active pharmaceutical ingredient (API) as gift sample.

REFERENCES

1. https://www.drugbank.ca
2. https://www.fda.gov


